Thurston, Springer, Miller, Herd & Titak, Inc. Alkermes Plc. Transaction History

Thurston, Springer, Miller, Herd & Titak, Inc.

$330 Million
Q3 2024

1 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2024 May 14, 2024	BUY	$26.4 - $32.56 $6,230 - $7,684	236 New	236 $6,000

Others Institutions Holding ALKS

# of Institutions

362

Shares Held

181M

Call Options Held

175K

Put Options Held

96.6K

Black Rock Inc. New York, NY

29.1M
Shares

$863 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

19M
Shares

$563 Million
0.01% of portfolio
Price T Rowe Associates Inc Baltimore, MD

13M
Shares

$385 Million
0.04% of portfolio
Wellington Management Group LLP Boston, MA

12.7M
Shares

$375 Million
0.06% of portfolio
State Street Corp Boston, MA

9.19M
Shares

$272 Million
0.01% of portfolio

View Full List

About Alkermes plc.

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.87B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

More about ALKS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Thurston, Springer, Miller, Herd & Titak, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Thurston, Springer, Miller, Herd & Titak, Inc. with notifications on news.

Account